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Abstract
Objective—Our objectives were to characterize the interrelation of known dementia-related 
neuropathologies in one comprehensive model and to quantify the extent to which accumulation of 
neuropathologies accounts for the association between age and dementia.
Methods—We used data from 1,362 autopsied participants of three community-based clinico-
pathologic cohorts: the Religious Orders Study, the Rush Memory and Aging Project, and the 
Minority Aging Research Study. We estimated a series of structural equation models summarizing 
a priori hypothesized neuropathological pathways between age and dementia risk individually and 
collectively.
Results—At the time of death (mean age: 89 years), 44% of our sample had a clinical dementia 
diagnosis. When considered individually, our vascular, amyloid/tau, neocortical Lewy body, and 
TAR DNA-binding protein 43 (TDP-43)/hippocampal sclerosis pathology pathways each 
accounted for a substantial proportion of the association between age and dementia. When 
considered collectively, the four pathways fully accounted for all variance in dementia risk 
previously attributable to age. Pathways involving amyloid/tau, neocortical Lewy bodies, and 
TDP-43/hippocampal sclerosis were interdependent, attributable to the importance of amyloid beta 
plaques in all three. The importance of the pathways varied, with the vascular pathway accounting 
for 32% of the association between age and dementia, while the remaining three interrelated 
degenerative pathways together accounted for 68% (amyloid/tau: 24%, the Lewy body: 1%, and 
TDP-43/hippocampal sclerosis: 43%).
Interpretation—Age-related increases in dementia risk can be attributed to accumulation of 
multiple pathologies, each of which contributes to dementia risk. Multi-pronged approaches may 
be necessary if we are to develop effective therapies.
INTRODUCTION
Multiple age-related neuropathologies are increasingly recognized as contributors to 
dementia risk.1-6 Although dementia is most commonly associated with Alzheimer’s disease 
(AD) neuropathology, namely amyloid beta plaques and neurofibrillary tangles, pure AD is 
relatively rare; the majority of dementia cases clinically diagnosed with probable AD show 
evidence of multiple neuropathologies.4, 7-11 Even among pathologically confirmed AD 
cases, significant co-morbidities are common and are frequently associated with worse 
clinical outcomes. For instance, for a given level of AD neuropathology, the presence of 
infarcts12 or cortical microinfarcts13 is associated with greater cognitive impairment, 
suggesting that underlying vascular disease increases dementia risk independent of AD 
neuropathology. Cerebral amyloid angiopathy (CAA), which commonly co-exists with AD 
pathology and which is associated with other features of cerebrovascular disease,14 is also 
independently associated with cognitive impairment and dementia.15, 16 Although Lewy 
bodies can contribute to dementia risk in the absence of AD neuropathology, Lewy bodies 
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are common in persons with pathologically confirmed AD,17, 18 and individuals with both 
AD pathology and Lewy bodies show greater risk of cognitive decline or dementia.19-21 
Likewise, TAR DNA-binding protein 43 (TDP-43) aggregations are common in aging, in 
pathologically confirmed AD, and in combination with hippocampal sclerosis,22, 23 and 
TDP-43 aggregations increase the likelihood of dementia, including a clinical diagnosis of 
AD.7, 24
The extent to which these neuropathological pathways interrelate and whether known 
neuropathologies can fully account for age-related increases in dementia risk is currently 
unknown. A fuller understanding will be critical to the development and targeting of 
effective therapies. Using structural equation modeling (SEM), we tested the significance 
and interrelations of all major dementia-related neuropathologies by which age was 
hypothesized to elevate dementia risk in an autopsy sample of persons recruited from the 
community.
METHODS
Study Sample
We used clinical and neuropathological data from autopsied participants of three Rush 
Alzheimer’s Disease Center clinical-pathologic cohorts of aging: the Religious Orders Study 
(ROS),25 the Rush Memory and Aging Project (MAP),26 and the Minority Aging Research 
Study (MARS).27 Briefly, ROS began in 1994 and recruited older Catholic nuns, priests, and 
brothers from religious orders across the United States. Participants were enrolled from over 
40 groups and included communally-living employed and retired persons. MAP began in 
1997 and recruited older adults living in retirement communities and subsidized housing 
facilities across the Chicago metropolitan area. MARS began in 2004 and recruited older 
adults who self-identified as African American or Black from churches, subsidized senior 
housing facilities, retirement communities, clubs, and organizations in the Chicago 
metropolitan area. Recruitment efforts involved relationship-building with local 
communities and consultation with community-based advisory groups. These three cohorts 
are designed to allow combined analyses. For all three, eligibility criteria required absence 
of recognized dementia at recruitment and agreement to annual clinical evaluations and 
cognitive testing. Participation in ROS and MAP required brain donation at death. MARS 
participants were asked, but not required, to donate starting in 2010. At the time of writing, 
the three studies had enrolled 4,094 subjects, and follow-up rates exceeded 90% of 
survivors. All three studies were approved by the institutional review board of Rush 
University Medical Center. All participants in our sample signed an informed consent and an 
Anatomical Gift Act form.
At the time of analyses, 1,744 participants had died and autopsies had been completed on 
1,418 (81.3%) participants. Our sample consists of the 1,362 persons with valid 
neuropathology data and a final consensus cognitive diagnosis of cognitive status prior to 
death.
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Measures
Age at death was based on self-reported date of birth and known date of death. Cognitive 
diagnosis proximate to death was determined by a neurologist with expertise in dementia 
who reviewed the available clinical data (i.e. interview data, medical history and 
examination data, neuropsychological testing, and annual diagnostic classification). For 
difficult cases, diagnosis was ascertained by consensus at a case conference including at 
least one neurologist and one neuropsychologist. All cognitive diagnoses were made blinded 
to postmortem data. AD dementia was classified according to NINCDS-ADRDA criteria;28 
less common dementia subtypes were classified according to accepted criteria or 
contemporary standards.29-31 For this analysis, Individuals with a dementia diagnosis 
according to any dementia criteria were classified as having dementia.
Brain autopsies were standardized and completed by study personnel blinded to clinical 
information.4, 32, 33 Briefly, each brain hemisphere was cut in coronal 1-inch slabs. One 
hemisphere was fixed in 4% paraformaldehyde and then cut, while the other was 
immediately photographed and frozen. Regions of interest were dissected from the fixed 
slabs and embedded in paraffin; sections of the paraffin blocks were cut and stained to 
characterize pathologies. All measures were reviewed by a board-certified neuropathologist.
Neuritic plaques and neurofibrillary tangles (tangles) were counted during microscopic 
examination of Bielschowsky silver-stained 6 micron sections on slides from 5 regions 
(hippocampus, midfrontal cortex, midtemporal cortex, inferior parietal cortex, and entorhinal 
cortex). Total number was counted within a 1 mm2 area of apparent greatest density of each 
index. We scaled regional counts of neuritic plaques and tangles by dividing the count of 
each region by the corresponding standard deviation. Scaled regional counts of neuritic 
plaques were averaged to provide a single neuritic plaques summary measure. Latent 
variable summaries of mesiotemporal and neocortical tangles were derived from scaled 
regional counts of tangles for use in analyses. Fixed slabs or photographs were evaluated for 
evidence of gross infarcts; we quantified gross infarcts as counts of visualized, dissected, 
and histologically confirmed chronic macroscopic infarcts. Paraffin-embedded sections from 
a minimum of 9 brain regions stained with hematoxylin/eosin (midfrontal cortex, middle 
temporal cortex, inferior parietal cortex, entorhinal cortex, hippocampus cortex, basal 
ganglia, thalamus, and midbrain) were used to characterize burden of microinfarcts, defined 
as infarcts identified by microscopy but not gross visual examination. We considered the 
count of ascertained microinfarcts across all sections. Macroscopic and microscopic infarct 
counts were parameterized as 0, 1, or ≥2 infarcts. Neuropathologists characterized cerebral 
atherosclerosis, arteriolosclerosis, and CAA using an ordinal scale ranging from 0 (none) to 
3 (severe). Ratings of atherosclerosis were based on visual examination of the Circle of 
Willis, arteriolosclerosis was quantified based on evaluation of the small vessels of the 
anterior basal ganglia, and CAA was assessed based on evaluation of paraffin-embedded 
sections of four neocortical regions (midfrontal, middle temporal, inferior parietal, and 
occipital) immunostained for beta-amyloid (antibody, Covance Labs, Dako, or Elan 
Pharmaceuticals).32 Lewy body disease was ascertained as present, brainstem-predominant, 
limbic-type, or neocortical-type based on evaluation of alpha-synuclein immunostained 
sections (antibody, Zymed or Wako) from multiple brain regions and a modified version of 
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the McKeith criteria.34 We considered only the presence or absence of neocortical Lewy 
body disease, as only neocortical Lewy bodies appear related to dementia.35 Severity of 
TDP-43 was quantified across six brain regions (amygdala, hippocampus CA1, 
hippocampus dentate, entorhinal cortex, middle temporal cortex, and midfrontal cortex) 
based on the number of cytoplasmic inclusions observed in the 0.25 mm2 area of greatest 
density after immunostaining for monoclonal antibodies to phosphorylated TDP-43 
(antibody, Ascenion). Each region was reviewed for neuronal and glial inclusions and rated 
on an ordinal 6-point scale. Total TDP-43 severity was quantified as the mean rating across 
the six regions. Hippocampal sclerosis was detected using H&E staining and the presence of 
severe neuronal loss in CA1 hippocampal subfield and/or subiculum. See http://
www.radc.rush.edu/docs/var/variables/htm for additional details.
Statistical Methods
We used SEM to estimate models including both latent and manifest variables that 
summarized our a priori hypothesized neuropathologic pathways between age and dementia 
risk, described below. These analyses tested whether our hypothesized models were 
consistent with the data and estimated the strength and significance of each hypothesized 
relation in our model. We estimated all parameters using weighted least squares with 
standard errors and mean- and variance-adjusted test statistics with a full weight matrix 
(WLSMV) which yields parameter estimates and standard errors that are robust to violations 
of multivariate normality. This method yielded measures of model fit and allowed use of 
data from all participants, even if data on certain variables were missing for some 
participants. Because several variables in our models were categorical, we report 
standardized parameter estimates from WLSMV estimation to enable more direct 
comparisons of magnitude of effects for different pathways to dementia. We used the χ2 
statistic and several practical fit indices when evaluating model fit to data, including the root 
mean square error of approximation (RSMEA), comparative fit index (CFI), Tucker-Lewis 
index (TLI), and standardized root mean square correlation (SRMR). An RSMEA ≤ 0.05, 
CFI > 0.95, TLI > 0.95, and SRMR < 0.08 indicate close model fit to data.36
To begin, we used confirmatory factor analysis (CFA) to model latent variables summarizing 
a subset of pathologies. A priori, we hypothesized a latent variable for (a) vessel disease, 
informed by measures of arteriolosclerosis and atherosclerosis, (b) infarcts, informed by 
measure of gross and micro cerebral infarcts, (c) neocortical tangles, informed by tangles in 
the inferior parietal, midfrontal, and midtemporal cortices, and (d) mesiotemporal tangles, 
informed by tangles in the entorhinal and hippocampus cortices. Assessment of model fit 
supported a modification allowing midtemporal tangles counts to inform both the 
neocortical and mesiotemporal tangles latent constructs. This alternate parameterization was 
added to our a priori hypothesized path model (summarized with this modification in Figure 
1) and was used in all subsequent SEM models involving this pathology. Use of alternate 
scorings for the cerebral infarct indicators did not appreciably change CFA results. Results 
of the CFA are available in Table s1.
After building these measurement models, we considered a series of structural models. 
Model 0 characterized the overall relation of age and dementia. Models 1 to 4 characterize 
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four a priori hypothesized pathologic pathways thought to mediate the association of age and 
dementia: a vascular pathway (Model 1), an amyloid/tau pathway (Model 2), a Lewy body 
disease pathway (Model 3), and a TDP-43/hippocampal sclerosis pathway (Model 4). 
Finally, we considered a full model (Model 5, Figure 1) incorporating all four pathways and 
their hypothesized interrelations.
We conducted several sensitivity analyses. First, to consider other paths considered but 
excluded from our a priori model, we evaluated whether there was statistical justification for 
adding a path from infarcts to neuritic plaques, a path from neuritic plaques to hippocampal 
sclerosis, or a path from CAA to infarcts. Second, we used two-group modelling to 
determine whether results varied across data source (MAP and ROS; MARS participants 
were excluded due to small numbers of MARS participants), across sex, or across persons 
from different birth cohorts. Two-group analyses of birth cohort addressed concerns that the 
distribution of pathologies could differ across those who died early or late relative to their 
peers. If so, then our sample would be enriched in pathologic patterns characteristic of those 
who died prematurely and our results would not be generalizable. Thus, we defined a group 
born before 1915, who would be extremely unlikely to remain alive through the end of our 
sampling period and compared whether our structural model was consistent in those born 
before 1915 (who are representative of all dead individuals) and those born after 1915 
(enriched in those who died prematurely). For each of our two-group comparisons, we 
confirmed measurement invariance prior to proceeding. All statistical analyses were 
completed using Mplus (Version 8) or STATA (Version 14). Throughout, we consider a p-
value <0.05 to be statistically significant.
RESULTS
The demographic and clinical characteristics of our sample are summarized in Table 1. On 
average, our sample was 89 years old at death (range: 65 to 108). Of the 44% with a clinical 
dementia diagnosis prior to death, 85% were diagnosed with AD dementia without a second 
cause of cognitive impairment, 11% were diagnosed with AD dementia with a second cause 
of cognitive impairment (e.g., stroke), and 4% were diagnosed with a non-AD primary cause 
of dementia. Brain pathology at autopsy was common regardless of dementia status. Age 
was significantly related to risk of dementia (OR: 1.79, 95% CI: 1.51, 2.12 per 10 years 
increase in age). This is represented by a standardized coefficient of 0.24 standard deviation 
(SD) units (SE = 0.03); see Table 2 (Model 0).
Model 1: Vascular Pathway
To model the vascular pathway, we allowed the relation between age and dementia to be 
mediated by latent variables for vessel disease and infarcts (Figure 2, Table 2: Model 1). Age 
had a significant direct effect on vessel disease, but not on infarcts. Vessel disease had a 
strong association with infarcts. Both vessel disease and infarcts had significant, independent 
associations with dementia. However, the direct effect of age on dementia remained large 
and significant (standardized coefficient β = 0.16, SE = 0.04).
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Model 2: Amyloid/tau pathway
Next, we considered an amyloid/tau pathway, allowing the relation between age and 
dementia to be mediated by neuritic plaques, our neocortical and mesiotemporal tangles 
latent variables, and CAA (Table 2: Model 2). A priori, age was specified to have direct 
effects on neuritic plaques, neocortical tangles, mesiotemporal tangles, and CAA, in addition 
to its direct effect on dementia. Neuritic plaques were hypothesized to have direct effects on 
neocortical tangles, mesiotemporal tangles, and CAA. In turn, the two tangles latent 
variables and CAA were hypothesized to have direct effects on dementia. In considering 
potential modifications, the addition of a direct effect of neuritic plaques on dementia (Table 
2: Model 2a) improved model fit; we accepted the model with this modification as the final 
amyloid/tau model. Parameter estimates for Model 2a are shown in Figure 3. Age had 
significant direct effects on neuritic plaques, mesiotemporal tangles, and CAA, but not 
neocortical tangles. Neuritic plaques had significant direct effects on neocortial tangles, 
mesiotemporal tangles, CAA, and dementia. The neocortial tangles latent variable had a 
significant effect on dementia, as did CAA, but the effect of the mesiotemporal tangles 
factor on dementia was non-significant. As with the vascular model, when considered 
independently, the amyloid model only partially mediated the effect of age on dementia, as 
the direct effect of age on dementia remained substantial and significant (standardized 
coefficient β = 0.21, SE = 0.03).
Model 3: Lewy body pathway
Third, we considered a neocortical Lewy body pathway. We hypothesized that age would 
have direct effects on neuritic plaques, presence of neocortical Lewy body disease, and 
dementia; that neuritic plaques would have a direct effect on neocortical Lewy body disease; 
and the neocortical Lewy body measure would have a direct effect on dementia. This model 
had very poor fit (Table 2: Model 3). The only possible modification was to include a direct 
effect of neuritic plaques on dementia. The modified model (Table 2: Model 3a) was 
saturated, and was accepted as the final Lewy body model. However, this result suggested 
that considering the Lewy body pathway separately from the amyloid/tau pathway or other 
hypothesized pathways involving neuritic plaques is inappropriate. Parameter estimates for 
Model 3a are shown in Figure 4. Age had a small direct effect on neuritic plaques and a non-
significant, essentially zero direct effect on Lewy body pathology. Neuritic plaques had 
significant effects on both Lewy body pathology and dementia. Lewy body disease had a 
substantial direct effect on dementia. As in previous models, the direct effect of age on 
dementia (standardized coefficient β = 0.21, SE = 0.03), remained large and significant, 
indicating that the neocortical Lewy body disease pathway only partially mediated the age-
dementia relation.
Model 4: TDP-43/hippocampal sclerosis pathway
Fourth, we considered a pathway involving TDP-43 and hippocampal sclerosis. Because 
neuritic plaques were again implicated in TDP-43 and hippocampal sclerosis, these three 
variables were included a priori along with age and dementia. The a priori form of Model 4 
assumed that neuritic plaques would affect dementia only indirectly through its effects on 
TDP-43 and hippocampal sclerosis, but had poor fit to the data (Table 2: Model 4). This 
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again necessitated the addition of a direct path from neuritic plaques to dementia, resulting 
in Model 4a (Table 2: Model 4a), which had very good fit and was accepted as the final 
model. However, as above, this indicated that considering TDP-43 and hippocampal 
sclerosis independent of other pathways involving neuritic plaques may not be appropriate. 
Parameter estimates for Model 4a are shown in Figure 5. Age had direct effects on both 
TDP-43 and hippocampal sclerosis. Neuritic plaques had a significant effect on TDP-43. 
Both neuritic plaques and hippocampal sclerosis had relatively large effects on dementia, but 
the direct effect of TDP-43 on dementia was non-significant. However, the direct effect of 
age on dementia (standardized coefficient β = 0.11, SE = 0.04) remained significant, 
indicating that the TDP-43/hippocampal sclerosis pathway did not fully mediate the age-
dementia relation.
Model 5: All pathologies combined
We then considered a model incorporating all four pathways simultaneously (Figure 1). This 
model fit the data well (Table 2, Model 5). However, five path coefficients were non-
significant: the effects of age on infarcts, neocortical tangles, and Lewy body disease; the 
effect of vessels on neuritic plaques; and the effect of TDP-43 on dementia. When these five 
path coefficients were fixed at zero, the resulting model had slightly improved fit to the data 
(Table 2: Model 5a). However, as this has little appreciable impact on the fit (Table 2), 
parameter estimates (Table s2), or percentage of the effect of age on dementia mediated by 
each path, we discuss Model 5 here and in Figure 6.
Direct effects of variables on one another are similar to those discussed for the modeling of 
separate pathways, although the addition of a direct path between neuritic plaques and 
dementia, added to improve model fit in Models 2a, 3a, and 4a, was not necessary here. 
Model fit worsened significantly if the path coefficients associated with any particular sub-
model (e.g., the path coefficients contained in the vascular pathway) were fixed to zero. 
Similar worsening of model fit occurred if previously important individual path coefficients 
were fixed at zero. Unlike in the models for the individual pathways, the direct effect of age 
on dementia in Model 5 was essentially zero, (standardized coefficient: β = 0.01, SE = 0.04) 
and non-significant; thus, the four pathways to dementia, taken together, fully mediated the 
relation between age and dementia. In this combined model, the vascular pathway accounted 
for 32% of the association between age and dementia, while the remaining three pathways, 
all of which involved neuritic plaques, accounted for 68% (the amyloid/tau pathway 
accounted for 24%, the Lewy body pathway accounted for 1%, and the TDP-43/
hippocampal sclerosis pathway accounted for 43%). (Recognizing that CAA can also be 
considered a vascular pathology, if we add the paths through CAA to our previously defined 
vascular pathway, these collectively account for 36% of the association between age and 
dementia.)
Sensitivity analyses were consistent with primary analyses. There was no evidence to 
support the addition of paths from infarcts to neuritic plaques, neuritic plaques to 
hippocampal sclerosis paths, or CAA to infarcts (all p>0.3). No significant differences in 
Model 5 were found by sample source (MAP versus ROS) or by sex.37, 38 When dividing 
our sample into those born before or after 1915 and allowing the path coefficients to be 
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estimated freely, the statistical index of fit worsened notably (χ2(176) = 276.97, p < .001), 
but the model had excellent global fit (RMSEA: 0.029, CFI: 0.987, TLI: 0.983). Further 
analyses suggested allowing the path coefficient from neuritic plaques to neocortical tangles 
to differ across groups; the resulting model had improved statistical model fit (χ2(24) = 
23.62, p = .48) and the standardized coefficient was β = 0.41 (SE = 0.01) for those born 
before 1915, and β = 0.57 (SE = 0.01) for those born after 1915, indicating a difference in 
magnitude but not presence or direction of association across groups.
DISCUSSION
Overall, our results demonstrate that accumulation of known pathologies, including 
cerebrovascular disease, amyloid/tau, CAA, neocortical Lewy bodies, TDP-43, and 
hippocampal sclerosis, completely account for the increased risk of dementia with age. In 
the combined model, all four pathways remain important, indicating that each pathway 
uniquely contributes to the age-related increase in risk of dementia. Our models also suggest 
interrelations between the amyloid/tau, Lewy body, and TDP-43/hippocampal sclerosis 
pathways. Specifically, neuritic plaques appear related to neurofibrillary tangles, CAA, 
neocortical Lewy body disease, and TDP-43, and after accounting for the association 
between neuritic plaques and these other pathologies, neuritic plaques had no direct effect on 
dementia. This suggests a significant contribution of amyloid beta to dementia through 
multiple pathways, not simply through influence on tangles. Importantly, although neuritic 
plaques appeared related to CAA and TDP-43/hippocampal sclerosis, these pathologies also 
appear to mediate the elevated risk of dementia on age through pathways that do not involve 
neuritic plaques. Finally, our model supports independence between the collective influence 
of the amyloid/tau, Lewy body, and TDP-43/hippocampal sclerosis pathways from our 
vascular pathway, with the vascular pathway accounting for 32% of the variance in dementia 
risk attributable to age, and the remaining pathways collectively accounting for 68%.
This work is generally consistent with prior work. Multiple studies have shown that vascular, 
amyloid/tau, Lewy bodies, and TDP-43/hippocampal sclerosis pathologies all contribute to 
cognition in older ages.8 Interestingly, despite suggestion of a synergistic relation in other 
contexts12, our work confirms prior work in ROS/MAP and elsewhere suggesting that 
vascular pathology does not interact with AD pathology to promote dementia.3, 39-41 
Nonetheless, the relative contribution of various pathologic pathways may differ by 
cognitive outcome. For example, in prior work in ROS/MAP, a vascular pathway accounted 
for 20% of variance in the association between age at death and pre-death decline in 
episodic memory and 29% of the variance in the corresponding association with decline in 
non-episodic memory.42
Little is known about the impact of TDP-43 and hippocampal sclerosis on cognition and 
dementia, alone or in the context of other pathologies. In the current analysis, the effect of 
TDP-43 on dementia risk was completely mediated by hippocampal sclerosis. However, we 
and others have reported that TDP-43 is independently associated with worse episodic 
memory, cognitive decline, and increased odds of dementia.7, 43, 44 The source of this 
discrepancy remains unknown. Potential reasons include the omission of other pathologies 
in prior work, unique or synergistic effects of hippocampal sclerosis and TDP-43 on 
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domain-specific cognition, or the sparsity of persons in our sample with hippocampal 
sclerosis but no TDP-43 (n=11). Because hippocampal sclerosis has been reported to be 
segmental,45 neuropathological assessment of multiple sections of hippocampus may be 
necessary to fully characterize the condition. Regardless, further work on the relation among 
AD, TDP-43, and hippocampal sclerosis is warranted, particularly given that pathways 
involving these pathologies appear to mediate a large percentage of the age-related increase 
in dementia risk.
Our study extends prior attempts to characterize the collective impact of multiple 
pathologies on cognition in several important ways. Our study included all major 
pathologies thought to contribute to dementia risk, which, combined with an SEM approach, 
allowed us to describe and quantify the relative contributions of hypothesized pathways, not 
just individual predictors. Notably, use of SEM allowed us to think globally about complex 
causal relationships between pathologies, enabled by the use of latent variables, 
simultaneous consideration of individual variables as both predictors of an outcome and 
mediators of a different predictor-outcome relation, and established methods to assess 
overall motel fit. Our approach also addresses the novel question of whether the collective 
influence of known pathologies can account for the association between age and dementia 
risk. Prior studies have frequently considered only a subset of pathologies, taken a different 
approach, or addressed related, but distinct questions. For example, in prior work in ROS/
MAP, global Alzheimer pathology, amyloid, tangles, gross infarcts, microinfarcts, and 
neocortical Lewy bodies accounted for 41% of the total variance in the rate of cognitive 
decline prior to death.32 While this study was limited by omission of TDP-43, hippocampal 
sclerosis, and measures of vessel disease, it appears unlikely that 100% of the variance 
would be accounted for after inclusion of these additional factors. However, the conclusion 
that pathology cannot fully account for variation in cognitive decline is not necessarily at 
odds with our findings here. While we conclude that accumulating pathology fully mediated 
the elevation in risk of dementia observed with age, we did not address the related question 
addressed in this prior study of whether differences in pathology account for variance in 
measures of cognition among similarly aged persons.
This study had many strengths. Our large clinico-pathologic sample was recruited from the 
community prior to the known onset of dementia, and autopsies were performed on the vast 
majority of deceased participants. In addition, our conclusions were consistent across data 
sources, birth cohorts, and sex. Our results are arguably generalizable to the white general 
population. The study also benefited from high-quality clinico-pathologic data quantifying 
all the major dementia-related pathologies and study-based clinical dementia ascertainment 
derived from in-person examinations, which is less prone to misclassification than 
ascertainment based on medical records or similar sources.
This study also has limitations. Some degree of misclassification is expected. However, 
despite expected misclassification, we were able to account for all the variance in clinical 
dementia status associated with increasing age. Our data were cross-sectional. Thus, we 
cannot prove the temporal ordering or causal relations implied by our model. We can only 
conclude that our hypothesized model is or is not consistent with the data; we cannot 
conclude that we have identified the true underlying causal relations. Other hypothesized 
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models may also fit the data and may or may not better reflect the true underlying causal 
structure connecting age, neuropathology, and dementia. Our results may not be 
generalizable to all race/ethnic groups. Whether there are differences in prevalence of brain 
pathologies across race/ethnic groups remains unclear46-48 and whether such differences 
would translate into differences in the relative importance of particular pathways remains 
unknown. Similar work in more diverse samples is warranted. The relative contribution of 
various pathologic pathways may differ by cognitive outcome42 or by presence of specific 
genetic polymorphisms.49, 50 Future work should evaluate this possibility. Finally, we 
considered broad characterizations of neuropathologic pathways. More detailed models 
(e.g.,51) may reveal further insights. In particular, our models do not account for all vascular 
pathologies (e.g., microbleeds, damaged neurovascular unit, etc.) or functional/molecular 
processes (e.g., contractility, glymphatic drainage, etc.).
Our findings have significant implications for clinical trial design and drug discovery. 
Efforts to develop therapies for AD have long targeted amyloid. While our analyses support 
the supposition that an effective anti-amyloid medication may have benefit on multiple 
pathologic pathways (if amyloid is truly causal and if treatment is given when maximally 
effective, likely decades prior to clinical symptoms) our results also suggest that it would be 
far from a panacea. Other pathologies clearly have independent and substantial contributions 
to dementia risk, even in our sample where the vast majority of cases were clinically 
diagnosed with AD and most had pathologic evidence of AD. These other pathologies 
should be considered valid therapeutic targets. Given the hypothesized complex pathways 
underlying dementia, a “one-size-fits-all” therapeutic strategy is unlikely to be successful. 
Drug discovery work, including clinical trials, will face numerous challenges in identifying 
persons likely to benefit from a given therapy, adequately powering studies to demonstrate 
benefit among this subgroup, and managing toxicity and cost considerations for patients 
with evidence of multiple pathologic processes.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hypothesized pathways by which neuropathology may mediate the association of age 
and dementia
Figure represents our a priori hypothesized model, with the addition of a modification 
allowing midtemporal tangles to contribute to the neocortical tangles latent variable. Squares 
or rectangles represent manifest variables and ellipses represent latent variables. Each 
single-headed arrow denotes a hypothesized unidirectional effect of one variable on another.
Abbreviations: Arter. Scler: arteriolosclerosis, CVDA: atherosclerosis, Gross: gross infarcts, 
Hippo. Sclerosis: hippocampal sclerosis; Mesio Tangles: Mesiotemporal tangles, Micro: 
microinfarcts, Neocort Tangles: neocortical neurofibrilary tangles, TDP: TAR DNA-binding 
protein 43, T-EC: neurofibrillary tangles in the entorhinal cortex, T-Hip: neurofibrillary 
tangles in the hippocampus, T-IP: neurofibrillary tangles in the inferior parietal cortex, T-
MF: neurofibrillary tangles in the midfrontal cortex, T-MT: neurofibrillary tangles in the 
midtemporal cortex.
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Figure 2. Results of path analysis considering mediation by the vascular pathology pathway of 
the effect of age on dementia risk
Squares or rectangles represent manifest variables and ellipses represent latent variables. 
Each single-headed arrow denotes a hypothesized unidirectional effect of one variable on 
another. Numbers associated with effects are standardized regression coefficients (e.g., from 
age to dementia) or standardized factor loadings (i.e., from a latent variable to its indicators). 
Paths that were statistically significant at p<0.05 are represented by solid lines. Paths that 
were hypothesized but were not statistically significant at p<0.05 are denoted by dashed 
lines.
Abbreviations: Arter. Scler: arteriolosclerosis, CVDA: atherosclerosis (cerebrovascular 
disease of the artery), Gross: gross infarcts, Micro: microinfarcts.
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Figure 3. Results of path analysis considering mediation by the amyloid/tau pathway of the effect 
of age on dementia risk
Squares or rectangles represent manifest variables and ellipses represent latent variables. 
Each single-headed arrow denotes a hypothesized unidirectional effect of one variable on 
another. Numbers associated with effects are standardized regression coefficients (e.g., from 
age to dementia) or standardized factor loadings (i.e., from a latent variable to its indicators). 
Paths that were statistically significant at p<0.05 are represented by solid lines. Paths that 
were hypothesized but were not statistically significant at p<0.05 are denoted by dashed 
lines.
Abbreviations:, Neocort Tangles: neocortical neurofibrilary tangles, T-EC: neurofibrillary 
tangles in the entorhinal cortex, T-Hip: neurofibrillary tangles in the hippocampus, T-IP: 
neurofibrillary tangles in the inferior parietal cortex, T-MF: neurofibrillary tangles in the 
midfrontal cortex, T-MT: neurofibrillary tangles in the midtemporal cortex.
Power et al. Page 17
Ann Neurol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Results of path analysis considering mediation by the neocortical Lewy body pathology 
pathway of the effect of age on dementia risk
Squares or rectangles represent manifest variables and ellipses represent latent variables. 
Each single-headed arrow denotes a hypothesized unidirectional effect of one variable on 
another. Numbers associated with effects are standardized regression coefficients (e.g., from 
age to dementia) or standardized factor loadings (i.e., from a latent variable to its indicators). 
Paths that were statistically significant at p<0.05 are represented by solid lines. Paths that 
were hypothesized but were not statistically significant at p<0.05 are denoted by dashed 
lines.
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Figure 5. Results of path analysis considering mediation by the TDP43/hippocampal sclerosis 
pathway of the effect of age on dementia risk
Squares or rectangles represent manifest variables and ellipses represent latent variables. 
Each single-headed arrow denotes a hypothesized unidirectional effect of one variable on 
another. Numbers associated with effects are standardized regression coefficients (e.g., from 
age to dementia) or standardized factor loadings (i.e., from a latent variable to its indicators). 
Paths that were statistically significant at p<0.05 are represented by solid lines. Paths that 
were hypothesized but were not statistically significant at p<0.05 are denoted by dashed 
lines.
Abbreviations: Hippo. Sclerosis: hippocampal sclerosis; TDP: TAR DNA-binding protein 
43.
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Figure 6. Results of path analysis of combined pathologic pathways mediating the effect of age 
on dementia risk
Squares or rectangles represent manifest variables and ellipses represent latent variables. 
Each single-headed arrow denotes a hypothesized unidirectional effect of one variable on 
another. Numbers associated with effects are standardized regression coefficients (e.g., from 
age to dementia) or standardized factor loadings (i.e., from a latent variable to its indicators). 
Paths that were statistically significant at p<0.05 are represented by solid lines. Paths that 
were hypothesized but were not statistically significant at p<0.05 are denoted by dashed 
lines.
Abbreviations: Arter. Scler: arteriolosclerosis, CAA: cerebral amyloid angiopathy; CVDA: 
atherosclerosis, Gross: gross infarcts, Hippo. Sclerosis: hippocampal sclerosis; Micro: 
microinfarcts; Mesio. Tangles: mesiotemporal neurofibrilary tangles; Neocort Tangles: 
neocortical neurofibrilary tangles, TDP: TAR DNA-binding protein 43, T-EC: 
neurofibrillary tangles in the entorhinal cortex, T-Hip: neurofibrillary tangles in the 
hippocampus, T-IP: neurofibrillary tangles in the inferior parietal cortex, T-MF: 
neurofibrillary tangles in the midfrontal cortex, T-MT: neurofibrillary tangles in the 
midtemporal cortex.
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Table 1
Characteristics of the eligible sample overall and by dementia status at time of death
Total Clinical Dementia Diagnosis Prior to Death No Clinical Dementia Prior to Death
N (%) 1362 (100%) 594 (44%) 768 (56%)
Age at death, mean (SD) 88.6 (6.7) 90.0 (6.2) 87.5 (6.9)
Born before 1915, n (%) 389 (29%) 212 (36%) 177 (23%)
Male, n (%) 462 (34%) 187 (31%) 275 (36%)
Black, n (%) 53 (4%) 23 (4%) 30 (4%)
Study, n (%)
 MAP 670 (49%) 268 (45%) 401 (52%)
 ROS 675 (50%) 322 (54%) 353 (46%)
 MARS 17 (1%) 4 (1%) 13 (2%)
Neuritic plaques, mean (SD) 0.8 (0.8) 1.2 (0.9) 0.6 (0.7)
Neurofibrillary tangles, mean (SD)
 Entorhinal cortex 24.1 (21.4) 29.6 (22.7) 19.9 (19.4)
 Hippocampus 24.2 (28.0) 32.9 (31.2) 17.4 (23.1)
 Midtemporal cortex 6.0 (12.0) 10.7 (15.5) 2.4 (6.4)
 Inferior parietal cortex 2.6 (6.8) 4.8 (9.0) 0.9 (3.8)
 Midfrontal cortex 2.1 (6.2) 4.1 (8.5) 0.7 (2.8)
Gross infarcts, n (%)
 0 884 (65%) 333 (56%) 551 (71%)
 1 243 (18%) 116 (20%) 127 (17%)
 ≥2 233 (17%) 143 (24%) 90 (12%)
Microinfarcts, n (%)
 0 961 (71%) 392 (66%) 569 (74%)
 1 244 (18%) 117 (20%) 127 (17%)
 ≥2 155 (11%) 83 (14%) 72 (9%)
Atherosclerosis, n (%)
 0 (none) 250 (18%) 82 (14%) 168 (22%)
 1 632 (47%) 271 (46%) 361 (47%)
 2 378 (28%) 181 (31%) 197 (26%)
 3 (severe) 93 (7%) 56 (9%) 37 (5%)
Arteriolosclerosis, n(%)
 0 (none) 430 (32%) 154 (26%) 276 (36%)
 1 462 (34%) 201 (34%) 261 (34%)
 2 343 (25%) 163 (28%) 180 (24%)
 3 (severe) 114 (8%) 71 (12%) 43 (6%)
CAA, mean (SD) 1.1 (1.1) 1.4 (1.1) 0.9 (1.0)
Neocortical Lewy bodies, n (%) 167 (12%) 114 (19%) 53 (7%
Hippocampal sclerosis, n (%) 119 (9%) 94 (16%) 25 (3%)
TDP-43, mean (SD) 0.6 (1.0) 0.4 (0.7) 1.0 (1.2)
Abbreviations: CAA, cerebral amyloid angiopathy; MAP, Memory and Aging Project; MARS, Minority Aging Research Study; ROS, Religious 
Orders Study; TDP-43, TAR DNA-binding protein 43
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